A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors



Status:Active, not recruiting
Healthy:No
Age Range:18 - Any
Updated:9/5/2018
Start Date:May 2012
End Date:July 31, 2019

Use our guide to learn which trials are right for you!

A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors

This is a multi-center, open-label, dose finding, Phase Ib dose escalation study to estimate
the MTD(s) and/or RP2D(s) for the dual combination of LGX818 and MEK162 and the triple
combination of LGX818 and MEK162 and LEE011, followed each independently by a Phase II part
to assess the clinical efficacy and to further assess the safety of the combinations in
selected patient populations. Oral LGX818 and MEK162 will be administered on a continuous
schedule. Oral LEE011 will be administered once daily on a three weeks on, one week off
schedule. Patients will be treated until progression of disease, unacceptable toxicity
develops, or withdrawal of informed consent, whichever occurs first. A cycle is defined as 28
days. The dose escalation parts of the trial will be conducted in adult patients with BRAF
V600-dependent advanced solid tumors and is expected to enroll at least 18 patients for the
dual combination and at least 12 patients for the triple combination. The dose escalation
will be guided by a Bayesian logistic regression model (BLRM). Following MTD/RP2D
declaration, patients will be enrolled in three Phase II arms for the dual combination and
one Phase II arm for the triple combination. All patients will be followed for 30 days for
safety assessments after study drugs discontinuation. All patients enrolled in the Phase II
part of the study will be followed for survival.


Inclusion Criteria:

Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage IIIB
to IV per American Joint Committee on Cancer [AJCC]), or confirmed diagnosis of
non-resectable advanced metastatic colorectal cancer (mCRC), or any other indication upon
agreement with the Sponsor, whose disease has progressed despite previous antineoplastic
therapy or for whom no further effective standard therapy is available

- Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation

- Evidence of measurable disease as determined by RECIST v1.1

- World Health Organization (WHO) Performance Status ≤ 2

- Negative serum pregnancy test within 72 hours prior to the first study dose in all
women of childbearing potential

Exclusion Criteria:

Progressive disease following prior treatment with RAF-inhibitors in combination with
MEK-inhibitors

- Symptomatic or untreated leptomeningeal disease

- Symptomatic brain metastases. Patients are not permitted to receive enzyme inducing
anti-epileptic drugs

- Known acute or chronic pancreatitis

- History or current evidence of retinal disease, retinal vein occlusion or
ophthalmopathy

- Clinically significant cardiac disease

- Patients with abnormal laboratory values at Screening/baseline

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of oral LGX818/MEK162

- Previous or concurrent malignancy

- Pregnant or nursing (lactating) women

- For addition of LEE011 in the triple combination, congenital long QT syndrome or
family history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3,
brain metastases at baseline, abnormal coagulation results PT/INR >1.5 x ULN or aPTT
>1.5 x ULN.

Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
5
sites
Boston, Massachusetts 02114
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials